Douglas Dieterich
Expertise in
23
conditions

Dr. Douglas Dieterich

Gastroenterology
MSSM-Optical Shop
17 E 102nd St, 
New York, NY 
Offers Telehealth
45 Years of Experience
Expertise in
23
conditions
MSSM-Optical Shop
17 E 102nd St, 
New York, NY 

Overview

Douglas Dieterich is a Gastroenterologist practicing medicine in New York, New York. He has been practicing medicine for over 45 years.

Dr. Dieterich is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Cirrhosis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

He is actively involved in clinical research, co-authoring 145 peer reviewed articles and participating in 6 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

Mount Sinai Hospital
Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MSSM-Optical Shop
17 E 102nd St, New York, NY 10029

Additional Areas of Focus

Dr. Dieterich has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure, Other
Study Drug: Lisinopril
Study Phase: Phase 2
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

145 Total Publications

Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort.
Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort.
Journal: Journal of the International Association of Providers of AIDS Care
Published: April 23, 2026
Similar Doctors
Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology
Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology
Referral may be required

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (0.6 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Schiano is a Gastroenterologist practicing medicine in New York, New York. Dr. Schiano is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Splenectomy.

Expertise in
18
conditions
Dr. David Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David Katzka
Gastroenterology
Referral may be required

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (2.3 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist practicing medicine in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Expertise in
8
conditions
Dr. Bruce Sands
Gastroenterology
Expertise in
8
conditions
Dr. Bruce Sands
Gastroenterology
Referral may be required

MSSM-Optical Shop

17 E 102nd St, 
New York, NY 
 (0.2 miles away)
212-241-8100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Sands is a Gastroenterologist practicing medicine in New York, New York. Dr. Sands is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Crohn's Disease, Hemorrhagic Proctocolitis, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Douglas Dieterich

How do I make an appointment with Dr. Douglas Dieterich?

You can book an appointment with Dr. Douglas Dieterich by calling their office at 212-241-7270. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Douglas Dieterich a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Douglas Dieterich is classified as an Elite expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Douglas Dieterich specialize in?

While Dr. Douglas Dieterich is a Gastroenterology, they have specific expertise in Hepatitis, Hepatitis C, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Douglas Dieterich participate in research or clinical trials?

Yes. Dr. Douglas Dieterich has published 145 articles and abstracts on conditions like Hepatitis. You can view a list of Dr. Douglas Dieterich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Douglas Dieterich accept my insurance?

Dr. Douglas Dieterich accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 212-241-7270 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dieterich's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 10 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile